Overview

Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases

Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this research project is to test the effectiveness of nivolumab versus nivolumab together with ipilimumab for the treatment of melanoma brain metastases. Patients are eligible to join this study if they are aged 18 years or above and have been diagnosed with melanoma with brain metastases.
Phase:
Phase 2
Details
Lead Sponsor:
Melanoma Institute Australia
Collaborators:
Australia and New Zealand Melanoma Trials Group
Bristol-Myers Squibb
Melanoma and Skin Cancer Trials Limited
Treatments:
Antibodies, Monoclonal
Ipilimumab
Nivolumab